Year

Author

Focus

Field/Summary and Commentary

 

Baker et al.

Review

Drug Development

A general framework for describing various roles for biomarkers in cancer prevention research (early detection, surrogate endpoint, and cohort identification for primary prevention) and the phases in their evaluation.

2005

Fleming

Review

Methodology

Surrogate endpoints and FDA’s accelerated approval process.

 

Sargent et al.

Statistics

Oncology

Meta-analytic approach for surrogate validation.

 

Baker, 2006a

Statistics

Methodology

A simple meta-analytic approach for using a binary endpoint to predict the effect of intervention on true endpoint.

 

Korn et al.

Statistics

Methodology

Assessing surrogates as trial endpoints using mixed models.

2006

Weir and Walley

Statistics

Review

Statistical evaluation of biomarkers as surrogate endpoints: A literature review.

 

Baker, 2006b

Statistics

Review

Title: Surrogate endpoints: Wishful thinking or reality?

 

Finley Austin and Babiss

Review

Methodology

Where and how could biomarkers be used in 2016?

 

Qu and Case

Statistics

Statistics

Quantifying the indirect treatment effect via surrogate markers.

 

Desai et al.

Review

Cardiology

Blood pressure as an example of a biomarker that functions as a surrogate.

 

Hughes

Review

HIV Medicine

Initial treatment of HIV Infection: Randomized trials with clinical endpoints are still needed.



The National Academies | 500 Fifth St. N.W. | Washington, D.C. 20001
Copyright © National Academy of Sciences. All rights reserved.
Terms of Use and Privacy Statement